Payer formulary tier increases of apixaban: how patients respond and potential implications

CONCLUSION: The majority of patients continued on apixaban despite higher OOP cost, suggesting patients' reluctance to change treatment for non-medical reasons; however, 30% of patients discontinued OAC treatment after higher apixaban tier placement.PMID:37519272 | DOI:10.1080/03007995.2023.2232636

Source: Current Medical Research and Opinion - July 31, 2023 Category: Research Authors: Steven Deitelzweig Emi Terasawa Nipun Atreja Amiee Kang Dionne M Hines Amol D Dhamane Melissa Hagan Ahmed Noman Xuemei Luo Source Type: research